This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ventas, Inc. is a healthcare real estate investment trust (REIT) that is primarily engaged in acquisition and ownership of senior housing, R&I and healthcare properties, and leasing them to unaffiliated tenants or operating them through independent third-party managers. Ventas offers MOB management, leasing, marketing, facility development and advisory services to well-rated hospitals and health systems throughout the United States through its ownership interest in PMB Real Estate Services LLC and the company’s subsidiary, Lillibridge Healthcare Services, Inc. It also makes secured and non-mortgage loans and other investments relating to senior housing and healthcare properties or operators.
Ventas Q2 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises
by Zacks Equity Research
VTR's Q2 results reflect a year-over-year rise in revenues. The total property same-store NOI improves on strong performance across the business segments.
Ventas (VTR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Ventas (VTR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ventas (VTR) Beats Q2 FFO and Revenue Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of +2.35% and +3.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Ahead of Ventas (VTR) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for Ventas (VTR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Healthpeak Q2 FFO Meets Estimates, Same-Store NOI Rises Y/Y
by Zacks Equity Research
DOC's second-quarter results reflect the continued strong performance of its high-quality lab, outpatient medical and CCRC portfolios.
What's in the Offing for Ventas Stock This Earnings Season?
by Zacks Equity Research
While VTR's Q2 earnings are likely to have benefited from favorable SHOP operating trends and a well-diversified tenant base, high interest expenses may have hurt it.
Ventas (VTR) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Ventas Stock Gains 11.6% in 6 Months: Will the Trend Last?
by Zacks Equity Research
VTR is likely to gain from an aging population, rising healthcare expenses, favorable outpatient visit trends and accretive investments in its research portfolio.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Here's Why Ventas (VTR) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ventas (VTR) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Why Is Ventas (VTR) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Ventas (VTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ventas Issues Business Update, Raises 2025 Normalized FFO Guidance
by Zacks Equity Research
VTR provides a business update that highlights delivering profitable growth in senior housing. It also increased the 2025 normalized FFO per share guidance.
Why Ventas (VTR) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Key Reasons to Add Ventas Stock to Your Portfolio Right Now
by Zacks Equity Research
VTR is likely to gain from rising healthcare expenditures among senior citizens. Accretive investments in the research portfolio and solid balance sheet bode well.
Why Ventas (VTR) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Ventas Q1 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises
by Zacks Equity Research
VTR's Q1 results reflect higher same-store cash NOI due to SHOP same-store average occupancy growth.
Ventas (VTR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Ventas (VTR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ventas (VTR) Beats Q1 FFO and Revenue Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 2.44% and 4.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Medical Properties in Q1 Earnings?
by Zacks Equity Research
While MPW's Q1 earnings are likely to have benefited from the favorable healthcare industry trends, exposure to certain troubled operators may have hurt it.
SBA Communications Q1 AFFO & Revenues Beat Estimates, '25 View Raised
by Zacks Equity Research
SBAC's Q1 results reflect significant growth in site-development revenues. However, higher costs and interest expenses ail.